Sign in

Research summary ·

Cardiovascular safety in middle-aged and older men under testosterone replacement therapy: a systematic review and meta-analysis.

Written based on 1 research study on PubMed, searched on 15 Nov 2026.

What was studied

This review pooled results from trials of testosterone treatment. It looked at safety for the heart and blood vessels. The men were middle-aged and older. They had low or low-normal testosterone levels. In each trial, people were put into groups by chance. The review took in 31 trials with 9,437 people in total. Treatment lasted from 40 days to 36 months.

What they found

Compared with placebo, testosterone was linked to lower total cholesterol. It was also linked to lower triglycerides and LDL cholesterol. HDL cholesterol showed no clear change. On a treadmill test, men could exercise longer before a set heart tracing change. This was seen in studies lasting up to 14 weeks. Over 12 to 36 months, the wall of the neck artery got thinner. The review also saw a possible warning sign for heart rhythm problems. This possible signal came from data on 6598 people.

What it means for patients

The authors say testosterone seems to lower overall heart risk factors. This applies to men in midlife and later with low or low-normal levels. They also say it is not clear how much the rhythm signal matters.

Why it is not certain yet

The rhythm problem is only a possible safety signal. The authors state that its real effect on health is unclear. Trial lengths ranged from 40 days to 36 months. The treadmill results come from studies of up to 14 weeks. A review can only be as good as the studies in it.

Source

Cardiovascular safety in middle-aged and older men under testosterone replacement therapy: a systematic review and meta-analysis.

PubMed · PMID 42836912

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Male hypogonadism publications